Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07487376 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults | PHASE1 | RECRUITING | 32 | — | — | May 24, 2026 | May 1, 2027 | May 29, 2026 | 1 | Australia |
Incidence, severity, and relationship to study treatment of TEAEs and SAEs, as determined by clinical laboratory evaluations, vital signs, physical examinations, and ECGs.
| Arm | Type | Description |
|---|---|---|
| IBIO-600 (Cohort 1) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 2) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 3) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 4) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Name | Type | Description |
|---|---|---|
| IBIO-600 | DRUG | IBIO-600 Subcutaneous injection |
| Placebo | DRUG | Matching placebo; subcutaneous injection |
Inclusion Criteria: * Aged 18 to 65 years of age * In good general health, with no significant medical history * BMI between ≥ 27.0 and ≤ 34.90 kg/m2 * History of self-reported stable body weight (defined as change of no more or less than ± 5%) within 90 days of Screening. * Willingness to refrain ...